Pre-diabetes Clinical Trial
Official title:
Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.
The goal of this study is to evaluate the hypothesis that the addition of liraglutide, a
long-acting glucagon-like peptide 1 (GLP-1) analogue, to a calorie-restricted diet will lead
to greater weight loss than will a calorie-restricted diet alone in subjects who are older
(50 to 60 years of age), overweight/obese, and prediabetic. These individuals have been
selected for study because they are at greatly increased risk to develop type 2 diabetes
(2DM) and cardiovascular disease (CVD), and it is hypothesized that the addition of
liraglutide to a calorie-restricted diet will significantly decrease risk of these adverse
outcomes.
There is considerable evidence that GLP-I compounds, including liraglutide, improve glycemic
control in patients with manifest 2DM. However, there is relatively little information as to
the potential utility of these compounds in nondiabetic individual at greatly increased risk
of 2DM and CVD. This research proposal is aimed at providing some of this information by
quantifying the effects of liraglutide, a long-acting GLP-1 analogue, on weight loss,
insulin secretion, insulin action, and multiple CVD risk factors in a very high risk
group—older, overweight/obese, prediabetic individuals. Furthermore, by using specific
methods, not surrogate estimates, and avoiding the confounding effects of glucotoxicity, it
will be possible to gain new insights into the effects of GLP-1 on insulin secretion and
insulin action.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Enrolling by invitation |
NCT05367024 -
Broccoli Effect on Glycated Haemoglobin (HbA1c)
|
N/A | |
Withdrawn |
NCT02400450 -
Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes
|
N/A | |
Completed |
NCT02933424 -
Project Plant Protein: the P3 Study in Humans
|
N/A | |
Completed |
NCT02656212 -
Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)
|
Phase 1 | |
Completed |
NCT02330276 -
Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
|
Phase 1 | |
Completed |
NCT01488279 -
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
|
N/A | |
Completed |
NCT00831129 -
A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs
|
Phase 2/Phase 3 | |
Completed |
NCT00536250 -
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
|
N/A | |
Recruiting |
NCT05563090 -
Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools
|
||
Active, not recruiting |
NCT04991142 -
Models of Nutrition From Continuous Glucose Monitors
|
||
Completed |
NCT02759055 -
Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)
|
N/A | |
Completed |
NCT00775684 -
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
|
N/A | |
Completed |
NCT03695913 -
Continuous Glucose Monitoring (CGM) With a Low Carbohydrate Diet to Reduce Weight in Patients With Pre-Diabetes
|
N/A | |
Completed |
NCT04051008 -
CTSI Pilot: Improving Adherence to Diabetic Diet
|
N/A | |
Recruiting |
NCT04897945 -
A Shared Decision Making Intervention for Diabetes Prevention in Women With a History of Gestational Diabetes Mellitus
|
N/A | |
Not yet recruiting |
NCT04442451 -
Mechanisms of Fatigability With Diabetes
|
N/A | |
Not yet recruiting |
NCT05925933 -
High Protein Diet on Transcriptomic, Metabolomics, Hepatic and Pancreatic Fat Anatomy and Physiology in Asian Indians With Pre-diabetes
|
N/A | |
Active, not recruiting |
NCT05654051 -
The SLIM LIVER Study
|
Phase 2 | |
Completed |
NCT02919397 -
Motivational Instant Messaging and E-diabetes Prevention Programme for High Risk of Type 2 Diabetes
|
N/A |